NovoSeven® RT was 93% effective at stopping nonsurgical and surgical bleeds in people with CFVIId.1,2,a
Congenital factor VII deficiency.
NovoSeven® RT is the only factor product approved for congenital factor VII deficiency (CFVIId).1

Congenital factor VII deficiency.
NovoSeven® RT is the only factor product approved for congenital factor VII deficiency (CFVIId).1



Offering the proven efficacy they expect.


aData from the published literature, compassionate use trials, and the Hemophilia and Thrombosis Research Society registry (HTRS) for patients with FVII deficiency (N=70) treated with NovoSeven® RT for 124 bleeding episodes, surgeries, or prophylaxis regimens. Dosing ranged from 6 to 98 mcg/kg administered every 2 to 12 hours (except for prophylaxis [doses administered from 2 times per day up to 2 times per week]). Patients were treated with an average of 1 to 10 doses. Treatment was effective if bleeding stopped or the physician rated the treatment as effective.1,2

Adjustable dosing.
Based on the severity of bleeding, adjust dose and frequency of injections to each individual patient.
bThe minimum effective dose has not been determined.
Dosing recommendation for CFVIId.1,b
CONGENITAL FACTOR VII DEFICIENCY
15-30 mcg/kg
every 4-6 hours
until hemostasis is achieved
Effective treatment has been achieved with doses as low as 10 mcg per kg body weight.
bThe minimum effective dose has not been determined.

The safety they deserve.
NovoSeven® RT is the only recombinant bypassing agent not made from human serum or proteins. Recombinant manufacturing minimizes the possibility of viral contamination.1,3
Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.1


The rapid access to treatment that keeps them on the go.
NovoSeven® RT is room temperature stable up to 77°F.1,c
cPrior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36–77°F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.

Quick reconstitution can save them time.
Every vial comes with a prefilled syringe, meaning no extra steps to fill a syringe with diluent.1,d
dCompared with reconstitution using histidine vials.
![Syringe and vial of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])](/content/dam/novonordisk/novosevenpro/clinicaldata/images/product-3-step-reconstitution.jpg)

Proven successful in the perioperative management of CFVIId.1


Calculate doses for your
patients living with CFVIId.

Looking for codes for
coagulation disorders?
